Duvelisib plus Romidepsin in Relapsed/Refractory T Cell Lymphomas: A Phase Ib/IIa Trial

Researchers conducted a Phase Ib/IIa study of duvelisib in combination with either romidepsin or bortezomib in patients with relapsed/refractory T cell lymphomas and found that the addition of romidepsin, but not bortezomib, appeared to increase efficacy while attenuating PI3K inhibitor-driven toxicity.